Ticker >

Remus Pharmaceutical share price

Remus Pharmaceuticals Ltd.

NSE: REMUS SECTOR: Trading  8314   23   2

8012.35
+260.50 (3.36%)
NSE: 03 May 03:47 PM

Price Summary

Today's High

₹ 8179.95

Today's Low

₹ 7860

52 Week High

₹ 8747

52 Week Low

₹ 1711.25

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1180.22 Cr.

Enterprise Value

1185.12 Cr.

No. of Shares

0.15 Cr.

P/E

138.8

P/B

17.66

Face Value

₹ 10

Div. Yield

0.03 %

Book Value (TTM)

₹  453.64

CASH

3.04 Cr.

DEBT

7.94 Cr.

Promoter Holding

70.6 %

EPS (TTM)

₹  57.73

Sales Growth

82.27%

ROE

66.14 %

ROCE

68.82%

Profit Growth

147.6 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 1 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year82.27%
3 Year55.74%
5 YearNA

Profit Growth

1 Year147.6%
3 Year118.81%
5 YearNA

ROE%

1 Year66.14%
3 Year59.33%

ROCE %

1 Year68.82%
3 Year70.26%

Debt/Equity

0.4151

Price to Cash Flow

222.14

Interest Cover Ratio

50.0920430107527

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 70.6 0
Sep 2023 69.61 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 55.7435624974268% for the Past 3 years.
  • Company has been maintaining healthy ROE of 59.3319129400185% over the past 3 years.
  • Company has been maintaining healthy ROCE of 70.2643282745611% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 50.0920430107527.
  • The company has an efficient Cash Conversion Cycle of -30.7674445172609 days.
  • The company has a high promoter holding of 70.6%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.0553173084552.
  • Promoter stake has increased from 0% to 69.61% in the last 1 quarter.

 Limitations

  • Company has contingent liabilities of 94.3569 Cr.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 97.7502.

Quarterly Result (All Figures in Cr.)

Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 11.92 18.42 24.7 45.03
Total Expenditure 11.53 17.66 20.57 34.48
Operating Profit 0.39 0.76 4.14 10.55
Other Income 0.85 0.81 0.72 1.58
Interest 0.04 0.04 0.09 0.23
Depreciation 0.11 0.18 0.15 0.48
Exceptional Items 0 0 0 0
Profit Before Tax 1.09 1.36 4.61 11.41
Tax 0.28 0.33 1.18 2.91
Net Profit 0.81 1.03 3.43 8.5
Adjusted EPS (Rs.) 8.12 10.26 34.34 78.37

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 0.01 0.01 1 1.09
Total Reserves 2.01 3.04 5.58 18.05
Borrowings 0.28 0.19 0.1 7.09
Other N/C liabilities 0.05 0.06 -0.04 0.15
Current liabilities 2.93 7.69 9.18 8.16
Total Liabilities 5.28 10.99 15.82 34.53
Assets
Net Block 0.5 0.39 0.31 2.54
Capital WIP 0 0 0 0.02
Intangible WIP 0 0 0 0
Investments 0 0.07 3.07 20.62
Loans & Advances 0.01 3.03 4.75 0.01
Other N/C Assets 0 0 0 0
Current Assets 4.76 7.5 7.69 11.34
Total Assets 5.28 10.99 15.82 34.53
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1.09 1.36 4.61 11.41
Adjustment 0.21 0.14 0 0.17
Changes in Assets & Liabilities 0.3 1.7 1.62 -3.27
Tax Paid -0.31 -0.36 -1.19 -3
Operating Cash Flow 1.3 2.84 5.04 5.31
Investing Cash Flow -0.56 -3.09 -4.55 -15.19
Financing Cash Flow 0.06 -0.12 -0.17 11.77
Net Cash Flow 0.81 -0.37 0.32 1.89

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Mar 2024%
promoters 69.61 70.60
anar swapnil shah 16.97 16.97
dhruvalben vishal shah 0.03 0.03
hemant ishwarlal modi 1.00 1.00
mansi aadarsh shah 0.07 0.07
renosen pharmaceuticals p... 0.07 0.70
roma vinodbhai shah 17.11 17.18
shah arpit deepakkumar 17.27 17.57
sonal hemantbhai modi 0.07 0.07
swapnil jatinbhai shah 16.97 16.97
vinodkumar gandalal shah 0.05 0.05
PARTICULARS Sep 2023% Mar 2024%
investors 30.39 29.40
iegfl - multi opportunity... 2.21 2.84
rekha gunavanth kumar 1.09 1.09
chhattisgarh investments ... 2.02 -
llp 0.31 -

Annual Reports

No Annual reports exist for this company.Report us

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

 No Latest News available for this company.
Report us

Remus Pharmaceutical Stock Price Analysis and Quick Research Report. Is Remus Pharmaceutical an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Remus Pharmaceutical . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Remus Pharmaceutical has a PE ratio of 138.800395664323 which is high and comparatively overvalued .

  • Share Price: - The current share price of Remus Pharmaceutical is Rs 8012.35. One can use valuation calculators of ticker to know if Remus Pharmaceutical share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Remus Pharmaceutical has ROA of 33.7728313562873 % which is a good sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Remus Pharmaceutical has a Current ratio of 1.38986498076405 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Remus Pharmaceutical has a ROE of 66.1354240801453 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Remus Pharmaceutical has a Debt to Equity ratio of 0.4151 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Remus Pharmaceutical has reported revenue growth of 82.2650307841145 % which is fair in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Remus Pharmaceutical for the current financial year is 23.4222349552383 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Remus Pharmaceutical is Rs 2 and the yield is 0.025 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Remus Pharmaceutical is Rs 57.7257 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Remus Pharmaceutical in Ticker for free. Also, one can get the intrinsic value of Remus Pharmaceutical by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Remus Pharmaceutical
X